Prestige Consumer Healthcare Inc.
NYSE•PBH
CEO: Mr. Ronald M. Lombardi CPA
セクター: Healthcare
業種: Medical - Distribution
上場日: 2005-02-10
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
連絡先情報
660 White Plains Road, Suite 250, Tarrytown, NY, 10591, United States
914-524-6800
時価総額
$3.22B
PER (TTM)
17.2
33.3
配当利回り
--
52週高値
$90.04
52週安値
$57.25
52週レンジ
順位45Top 56.8%
3.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2026 データ
売上高
$283.44M+0.00%
直近4四半期の推移
EPS
$0.98+0.00%
直近4四半期の推移
フリーCF
$75.26M+0.00%
直近4四半期の推移
2026 Q3 決算ハイライト
主なハイライト
Quarterly Net Income Decline Net income $46.7M, down 23.5% for the quarter; diluted EPS fell to $0.97 from $1.22.
Completed Pillar5 Acquisition Acquired Pillar5 on December 18, 2025; preliminary goodwill recorded totaled $52.6M in the period.
Operating Cash Flow Stronger Nine-month operating cash flow increased to $214.8M, up $25.1M, driven by working capital timing.
Gross Margin Stable Quarterly gross profit margin held steady at 55.5% despite revenue decline of 2.4% to $283.4M.
リスク要因
Supply Chain Disruptions Impact Continued shortages, delays, and backorders, particularly eye care products, negatively impacting sales results.
Rising Input Cost Pressure Volatile environment exacerbated rising input costs for raw materials, labor, and shipping impacting margins.
Customer Concentration Risk Dependence on limited customers; Walmart accounted for 18% of Q3 2025 gross revenues.
International Segment Gross Profit International segment gross profit dropped 11.6% quarterly due to inflation costs and unfavorable product mix.
見通し
Liquidity Position Adequate Cash from operations and credit facilities expected to finance working capital and capital expenditures next twelve months.
Share Repurchase Authorization $92.9M remaining under the $300.0M common stock repurchase program authorized in May 2024.
Acquisition Integration Focus Management expects to finalize valuations for recent acquisitions, including Pillar5 and Feminax asset allocations.
Debt Covenants Compliance Management anticipates compliance with all financial and restrictive debt covenants over the next twelve months.
同業比較
売上高 (TTM)
PRGO$4.28B
ICUI$2.32B
$2.16B
粗利益率 (最新四半期)
APLS94.7%
CPRX82.9%
RARE82.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| IMVT | $5.22B | -10.0 | -65.8% | 0.0% |
| INDV | $4.21B | 25.4 | -60.4% | 25.1% |
| ICUI | $3.51B | -476.2 | -0.4% | 33.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.5%
横ばい
4四半期純利益CAGR
-2.3%
収益性の安定
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月6日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2026
会計期末: 2025年12月31日|提出日: 2026年2月5日|売上高: $283.44M+0.0%|EPS: $0.98+0.0%予想を下回るForm 10-Q - Q2 2026
会計期末: 2025年9月30日|提出日: 2025年11月6日|売上高: $274.11M-3.3%|EPS: $0.86-21.8%予想を下回るForm 10-Q - Q1 2026
会計期末: 2025年6月30日|提出日: 2025年8月7日|売上高: $249.53M-6.6%|EPS: $0.96-2.0%予想を下回るForm 10-K - FY 2025
会計期末: 2025年3月31日|提出日: 2025年5月9日|売上高: $1.14B+1.1%|EPS: $4.32+2.6%予想を上回るForm 10-Q - Q3 2025
会計期末: 2024年12月31日|提出日: 2025年2月6日|売上高: $290.32M+2.7%|EPS: $1.23+15.0%予想を上回るForm 10-Q - Q2 2025
会計期末: 2024年9月30日|提出日: 2024年11月7日|売上高: $283.55M-1.0%|EPS: $1.10+1.9%予想通りForm 10-Q - Q1 2025
会計期末: 2024年6月30日|提出日: 2024年8月8日|売上高: $267.14M-4.4%|EPS: $0.98-8.4%予想を上回るForm 10-K - FY 2024
会計期末: 2024年3月31日|提出日: 2024年5月15日|売上高: $1.13B-0.2%|EPS: $4.21+355.2%予想を上回る